Survodutide engages two receptors: GLP-1 and glucagon. The glucagon arm is studied for effects on energy expenditure and liver fat, which is why Survodutide has drawn interest in metabolic and MASH/NAFLD research contexts — a different pairing from Tirzepatide's GLP-1/GIP.
Orforglipron is not a peptide at all — it's a small-molecule, orally available GLP-1 agonist. Its significance is the delivery route: a daily pill instead of an injectable peptide, without the food-and-water restrictions of peptide oral formulations. That makes it one of the most closely watched compounds in the pipeline.
| Compound | Mechanism | Notable feature |
|---|---|---|
| Semaglutide | GLP-1 (single) | Established benchmark |
| Tirzepatide | GLP-1 / GIP | Dual incretin |
| Retatrutide | GLP-1 / GIP / glucagon | Triple agonist |
| Survodutide | GLP-1 / glucagon | Glucagon arm (energy/liver) |
| Orforglipron | GLP-1 (small molecule) | Oral, once-daily |
As these compounds appear in the research-chemical market, PepsTracker tracks them across vendors and normalizes to cost-per-milligram with discount codes applied. See the wider field in best peptides for fat loss and Retatrutide vs Cagrilintide. Search either compound on the PepsTracker homepage for live pricing across 26 vendors.
Survodutide is a GLP-1/glucagon dual agonist, while Retatrutide is a GLP-1/GIP/glucagon triple agonist. Retatrutide adds the GIP receptor; both include the glucagon arm.
No. Orforglipron is a small-molecule, orally available GLP-1 receptor agonist — a daily pill rather than an injectable peptide.
PepsTracker normalizes all metabolic compounds to cost-per-milligram after discount codes across 26 vendors, so you can compare Survodutide, Orforglipron, Semaglutide, Tirzepatide and Retatrutide on the same basis.